Cardiometabolic Disorders News

ORLANDO — The GIP/GLP-1 dual agonist tirzepatide reduced symptoms of obstructive sleep apnea and improved multiple cardiometabolic markers for adults with obesity and obstructive sleep apnea, according to data from the SURMOUNT-OSA trial.

Late bedtime and too little or too much sleep were associated with higher odds for hypertension, hypertriglyceridemia and metabolic syndrome, according to a study published in Journal of the American Heart Association.

In patients with obesity and obstructive sleep apnea, those who had weight-loss surgery had approximately 40% reduced risk for major adverse CV events and death compared with those who did not, according to the results of the MOSAIC study.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.

The past 10 years have seen rapid growth in research on how endocrine-disrupting chemicals affect humans.

Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials are among the many highlights at the American Diabetes Association’s 84th Scientific Sessions.

Hypertension expert and longtime editorial board member for Healio | Cardiology and Healio | Endocrinology George L. Bakris, MD, died June 15, 2024, at the age of 72.

The National Lipid Association has issued a clinical consensus statement on the management of dyslipidemia in women of reproductive potential, with a focus on considerations for pharmacologic options, a speaker reported.

Fewer U.S. adults aged 40 to 75 years are eligible for statin therapy for primary CVD prevention in the new PREVENT risk calculator compared with the older Pooled Cohort Equation, researchers reported.

PHILADELPHIA — Some dietary change may improve cardiometabolic measures beyond weight loss and providers should create a diet that will most benefit each individual with obesity, according to a speaker.